Skip to Main Content
Skip Nav Destination

Biomarker Insights Intensify Anti-TIGIT Design Debate

March 14, 2024

Abstract: New research highlights the potential of TIGIT-directed antibody therapies to remodel immunosuppressive tumor microenvironments—but only if they contain functional Fc domains. The finding fuels ongoing debates on optimal antibody design, with late-stage trials underway of both Fc-active and Fc-inert candidates as treatments for non–small cell lung cancer and gastroesophageal cancer, among other tumor types.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal